Drug Information

Drug General Information
Drug ID
D0Y2ZN
Former ID
DNCL002128
Drug Name
Oral azacitidine
Indication Myelodysplastic syndrome [ICD9: 238.7; ICD10:D46] Phase 1 [524889], [531480]
Company
Celgene
Target and Pathway
Target(s) DNMT1 Target Info Inhibitor [528903]
KEGG Pathway Cysteine and methionine metabolism
Metabolic pathways
MicroRNAs in cancer
Pathway Interaction Database Regulation of retinoblastoma protein
PathWhiz Pathway Methionine Metabolism
Reactome PRC2 methylates histones and DNA
NoRC negatively regulates rRNA expression
DNA methylation
WikiPathways Trans-sulfuration and one carbon metabolism
Retinoblastoma (RB) in Cancer
One Carbon Metabolism
Trans-sulfuration pathway
References
Ref 524889ClinicalTrials.gov (NCT02223052) CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies. U.S. National Institutes of Health.
Ref 531480Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011 Jun 20;29(18):2521-7.
Ref 5289035-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007 Jun;6(6):1718-27.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.